Feasibility and safety of intravenous tolvaptan administration immediately upon ICU admission after cardiac surgery with cardiopulmonary bypass
Surgery Today · 10.09.2026
DOI: 10.1007/s00595-026-03470-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgery Today, online erschienen am 10.09.2026. Verfasst von Masahiko Narita und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Steel Memorial Muroran Hospital, Chiribetsucho 1-45, Muroran, 050-0076, Japan. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Tolvaptan sodium phosphate (TSP; Samtas ® , Otsuka Pharmaceutical, Tokyo, Japan) is a novel intravenous aquaretic diuretic; however, evidence for its use in patients after cardiac surgery is limited. We evaluated the early postoperative administration of TSP in patients who underwent cardiac surgery.
Methods
We enrolled 91 patients who underwent cardiac surgery with cardiopulmonary bypass at our institution. Of these, 46 received TSP immediately after intensive care unit admission, and 45 served as controls. After propensity score matching, 20 matched pairs were analyzed. A subgroup analysis was performed according to the renal function in TSP-treated patients.
Results
In the propensity score-matched cohort, the TSP group showed a trend toward adequate early postoperative urine output and a gradual negative fluid balance. Regarding safety, electrolyte abnormalities did not increase in the TSP group. No patient in either group developed significant acute kidney injury. Similar trends were observed in patients with a reduced renal function.
Conclusions
In this selected cohort, intravenous TSP administration immediately upon ICU admission after cardiac surgery with cardiopulmonary bypass was feasible and not associated with any major safety concerns, including in patients with a reduced renal function. TSP also tended to reduce day-to-day fluid balance fluctuations with an adequate urine output.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Steel Memorial Muroran Hospital, Chiribetsucho 1-45, Muroran, 050-0076, Japan.
- Department of Cardiac Surgery, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan.
- Department of Cardiac Surgery, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510, Japan. kyokui140021@gmail.com.
- Department of Cardiovascular Surgery, Kushiro Kojinkai Memorial Hospital, Aikoku, Kushiro, 191-212, 085-0062, Japan.
Zitieren
APA
Narita, M., Shirakura, K., Hikasa, E., Fukuta, H., Tamaru, Y., Nakatsu, T., Kadohama, T., Akasaka, N., & Kamiya, H. (2026). Feasibility and safety of intravenous tolvaptan administration immediately upon ICU admission after cardiac surgery with cardiopulmonary bypass. Surgery Today. https://doi.org/10.1007/s00595-026-03470-2
Vancouver
Narita M, Shirakura K, Hikasa E, Fukuta H, Tamaru Y, Nakatsu T, et al. Feasibility and safety of intravenous tolvaptan administration immediately upon ICU admission after cardiac surgery with cardiopulmonary bypass. Surgery Today. 2026. doi:10.1007/s00595-026-03470-2
BibTeX
@article{Narita2026,
author = {Narita, Masahiko and Shirakura, Kentaro and Hikasa, Eijiro and Fukuta, Hana and Tamaru, Yuya and Nakatsu, Tomoki and Kadohama, Takayuki and Akasaka, Nobuyuki and Kamiya, Hiroyuki},
title = {Feasibility and safety of intravenous tolvaptan administration immediately upon ICU admission after cardiac surgery with cardiopulmonary bypass},
journal = {Surgery Today},
year = {2026},
doi = {10.1007/s00595-026-03470-2}
}
EUVIMED